@article{aa852bb54162402d859fb08f9e864f38,
title = "Current Frontline Treatment of Multiple Myeloma",
abstract = "Treatment paradigms for management of newly diagnosed (ND) multiple myeloma have been evolving over the past 20 years as a consequence of the development of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. While recent studies have continued to confi rm the progression-free survival benefi t of consolidation with upfront autologous stem cell transplant in those considered transplant eligible (TE), the line between induction strategies for TE and transplant-ineligible (TI) patients has blurred, based on studies evaluating both populations. Here, we present an overview of the data guiding current treatment approaches in the ND setting and discuss areas of ongoing investigation, including the role of quadruplet combination therapies in TE patients, the optimal strategies for frail TI patients, and management of high-risk disease.",
author = "Holstein, {Sarah A.}",
note = "Funding Information: AstraZeneca, Bayer, Genentech, and Natera Inc; and has equity in Compass Therapeutics and Processa; SS has consulted for AstraZeneca, Genentech, Ipsen, Imvax Inc, and QED Therapeutics; NVU has consulted for AstraZeneca, BostonGene, Incyte, Helsinn Healthcare SA, QED Therapeutics, and Taiho Oncology, Inc.; has received research funding from EMD Serono, Ipsen, and Taiho Oncology, Inc.; and has long position holdings in Exact Sciences and Natera Inc. Funding Information: a consultant for Bristol Myers Squibb/ Celgene, GSK plc, Janssen Pharmaceuticals, Oncopeptides, Pfizer, Sanofi, Secura Bio, and Takeda Pharmaceutical Company; and has received research funding from Oncopeptides. Funding Information: The study was conceived in 2013 and a letter of intent for the protocol was approved by Genentech on September 4, 2014. The study was approved by the Yale University institutional review board on November 13, 2014, and activated for accrual on April 27, 2015. Genentech provided omalizumab as an investigational agent and partial financial support for the trial. Funding Information: funds from the Susan G. Komen Foundation. Telli is an associate professor of medicine (oncology) in the Division of Medical Oncology at Stanford University School of Medicine, director of the Stanford Cancer Institute{\textquoteright}s Breast Cancer Program, and associate director of the Stanford Women{\textquoteright}s Cancer Center. This year, the Susan G. Komen Foundation awarded $21.7 million to 48 new research projects across 26 different academic medical institutions. Publisher Copyright: {\textcopyright} 2022 UBM Medica Healthcare Publications. All rights reserved.",
year = "2022",
month = jul,
doi = "10.46883/25920967",
language = "English (US)",
volume = "36",
pages = "430--441",
journal = "Oncology (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7",
}